21:58 , May 24, 2019 |  BioCentury  |  Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
20:48 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the BRD4-FOXO3-CDK6 axis could help treat luminal breast cancer resistant to AKT inhibitors. In patients who had been treated for hormone receptor-positive luminal...
14:42 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammatory disease Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; cancer Patient sample, cell culture and mouse studies suggest inhibiting the METTL3-EIF3H interaction could help treat lung and other cancers. In tumor samples from patients with lung adenocarcinoma or seven other cancers,...
19:36 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture studies identified a pteridinylbenzamide-based dual PLK1/BRD4 inhibitor that could help treat AML. Chemical synthesis and screening of analogs of a pteridinylbenzamide-based tool compound PLK1 inhibitor in enzyme activity...
21:41 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Head and neck cancer Cell culture and mouse studies suggest BRD4 inhibitors could help treat cetuximab-resistant squamous cell carcinoma of the head and neck (SCCHN). In two human cetuximab-resistant SCCHN cell lines, cetuximab plus...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
15:26 , Apr 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Chronic lymphocytic leukemia (CLL) Patient sample, in vitro and mouse studies identified a BRD4 inhibitor that could help treat CLL. In B cells isolated from patients, BRD4 levels were higher than in B cells...
16:01 , Mar 26, 2018 |  BC Innovations  |  Translation in Brief

Tagging out

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...